Tradjenta, Trajenta (linagliptin) is a small molecule pharmaceutical. Linagliptin was first approved as Tradjenta on 2011-05-02. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Tradjenta's patents are valid until 2031-03-05 (FDA).
|Indication||type 2 diabetes mellitus|
|Drug Class||Dipeptidyl aminopeptidase-IV inhibitors|